Gonadotropin-releasing hormone [GnRH, also called luteinizing hormone releasing hormone or luliberin] is a decapeptide that is synthesized in the hypothalamus and interacts with GnRH receptors on gonadotrope cells in the anterior pituitary. GnRH stimulates the biosynthesis and release of luteinizing hormone and follicle-stimulating hormone, which in turn are required for steroidogenesis and gametogenesis, respectively. Because of this central role in reproduction, GnRH analogs have been used in a variety of therapeutic applications (Millar et al., 1987) .
Although an X-ray diffraction analysis of rhodopsin has recently been published (Palczewski et al., 2000) , most other G protein-coupled receptors (GPCR) are more difficult to purify. Consequently, understanding of the structure of these GPCRs is likely to depend on indirect methods, such as computational modeling and mutagenesis, for some time to come. Considerable advances have been made in understanding how GnRH interacts with its receptor. In the human GnRH receptor, residues Asp 2.61(98) , Trp 2.64(101) , Asn 2.65(102) , Lys 3.32(121) , and Asn 5.61(212) (residue numbering is described under Materials and Methods) have been shown to have roles in ligand binding (Zhou et al., 1995; Davidson et al., 1996; Flanagan et al., 2000; Hoffmann et al., 2000) . Some of these receptor residues have been proposed to form part of the ligand binding pocket, interacting with the amino and carboxyl termini of GnRH in a computational model of the receptor-ligand complex (Sealfon et al., 1997 interacts with Gly 10 -NH 2 . In the mouse GnRH receptor, Glu 7.32(301) was shown to have a role in recognizing the Arg 8 residue of GnRH (Flanagan et al., 1994) . However, Glu 7.32(301) is not completely conserved in mammalian GnRH receptors. In the human and other nonrodent GnRH recep-tors the equivalent residue is Asp 7.32(302) (Kakar et al., 1992; Chi et al., 1993; Illing et al., 1993; Sealfon et al., 1997; Cui et al., 2000) . Although this is a conservative substitution, it is surprising that such a functionally important residue is not absolutely conserved. In the monoamine receptors, the Asp 3.32 residue, which is important for ligand binding, is conserved as Asp not only in different species but also in different receptor subtypes that recognize the same ligand and in different receptors that recognize distinct ligands ranging through acetylcholine, adrenaline, serotonin, and histamine (Probst et al., 1992) .
In GnRH, Arg 8 is required for high-affinity binding to mammalian GnRH receptors. Substitution of this residue decreases GnRH potency and affinity for the receptor (Millar et al., 1989) . Mutation of the Glu 7.32(301) residue of the mouse GnRH receptor to Gln decreased the receptor affinity for GnRH, but not for analogs with substitutions for Arg 8 (Flanagan et al., 1994) . Subsequent models of GnRH receptor-ligand complexes have incorporated an interaction of the acidic residue of the receptor with Arg 8 of the ligand (Chauvin et al., 2000; Flanagan et al., 2000; Hoffmann et al., 2000) . However, a GnRH analog with D-Trp substituted in position six showed only a small decrease in affinity for the Glu 7.32(301) Gln mouse receptor. This suggested that although Glu 7.32(301) determines selectivity for native GnRH, the mechanism by which it does so may be more complex than a simple electrostatic interaction of Glu 301 with Arg 8 . It also indicates a need for caution in extrapolating experimental results to molecular models of GPCRs.
The lack of conservation indicates a need to determine whether Asp 7.32(302) has the same function in the human GnRH receptor as Glu 7.32(301) has in the mouse receptor. Furthermore, the incorporation of a direct interaction of Glu 7.32(301) /Asp 7.32(302) with Arg 8 in models of receptor-ligand complexes, despite evidence that a direct interaction may not always occur, shows that better definition of the mechanism by which the Asp 7.32(302) determines binding specificity for GnRH is needed. We now show that mutating Asp 7.32(302) in the human GnRH receptor decreases affinity for GnRH, but not for analogs with substitutions for Arg 8 . In contrast, a series of peptides with different structural constraints that stabilize a high-affinity conformation of GnRH retain high affinity for the mutant receptor. This indicates that an electrostatic interaction is not involved in the binding of these constrained analogs. We also show that Arg 8 is not required for high-affinity binding of constrained analogs. We interpret these results in terms of a sequential binding mechanism in which the Arg 8 side chain of native GnRH interacts transiently with Asp 7.32(302) , before interacting with a final ligand binding pocket that also binds constrained analogs.
Materials and Methods
Consensus Residue Numbering Scheme. A consensus numbering scheme is used to facilitate the comparison of equivalent amino acid residues in the different rhodopsin-like GPCRs (Ballesteros and Weinstein, 1995) . Amino acids were numbered relative to the most conserved residue in each transmembrane domain, which is assigned the number 50 (Fig. 1) . Individual amino acid residues are identified by a generic identifier consisting of the transmembrane helix number, followed by the number representing its position relative to the most conserved residue in the helix. This is followed by its sequential number in the particular GPCR. For example, the most conserved residue in helix seven of the GnRH receptor is Pro, which is designated Pro 7.50 . In the GnRH receptor, Pro 7.50 is residue number 320 and is designated Pro 7.50(320) . Asp 302 is 18 amino acids closer to the amino-terminal than Pro 7.50 and is therefore designated Asp 7.32(302) . Site Directed Mutagenesis. A polymerase chain reaction-based mutagenesis method was used to replace Asp 7.32(302) with Asn in the human GnRH receptor. Primers contained the desired mutation and a silent restriction endonuclease site flanked by 12 bases of the wild-type receptor sequence on either side. Polymerase chain reaction products were digested with appropriate restriction enzymes, ligated using T4 DNA Ligase (Amersham Pharmacia Biotech, Piscataway, NJ), subcloned into the EcoRI and XhoI sites of the mammalian expression vector pcDNAI/AMP (Invitrogen, Carlsbad, CA), and transformed into competent XL-1 blue Escherichia coli. Plasmid DNA was extracted (Nucleobond Kit; Macherey-Nagel, Duren, Germany) from ampicillin-resistant clones and the mutation was confirmed by DNA sequencing (Epicentre Technologies, Madison, WI).
Transfection and Cell Culture. COS-1 cells were transiently transfected using the DEAE-Dextran method (Keown et al., 1990) , as described previously . After transfection, COS-1 cells were cultured in Dulbecco's modified Eagle's medium (Invitrogen) containing 10% fetal calf serum (Delta Bioproducts, Kempton Park, South Africa) and antibiotics (2 mg/ml streptomycin sulfate, 4000 U/ml sodium benzylpenicillin) in a 10% CO 2 incubator at 37°C. ]-GnRH were prepared by solid phase synthesis on a 4-methylbenzhydrylamine HCl resin using Boc/Benzyl chemistry. The Boc-␥-lactam (Freidinger et al., 1980) was added as one amino acid unit. After removal from the resin by hydrogen fluoride, the peptides were purified to homogeneity by reverse-phase high-performance liquid chromatography on a C-18 preparative column. . Aspirating the medium and addition of 10 mM formic acid (1 ml/well) terminated the incubation. Inositol phosphates were extracted from the formic acid extract on DOWEX-1 ion exchange columns and eluted into scintillation liquid (Quicksafe; Zinsser Analytical, Frankfurt, Germany) and the radioactivity was counted.
Radioligand Binding. Membrane binding assays were performed because this method makes it possible to optimize receptor concentration by varying the amount of transfected membranes used in the assay . The agonist peptide, [His 5 ,D-Tyr 6 ]-GnRH, was radioiodinated by the Chloramine-T method as described previously (Flanagan et al., 1998) . Specific activity ranged between 900 and 1800 Ci/g and 69% of the radioactivity could be bound by GnRH receptors. Using this high-affinity label allowed accurate determination of IC 50 values for the mutant receptor, which had low total binding (Flanagan et al., 1998) . Transfected COS-1 cells were homogenized in binding buffer (1 mM EDTA, 10 mM HEPES, pH 7.4, 0.1% bovine serum albumin) and centrifuged at 15,000g for 30 min at 4°C. The resultant crude membrane pellet was resuspended in binding buffer. The membrane suspension was incubated overnight at 4°C with 125 I-[His 5 ,D-Tyr 6 ]-GnRH (50,000 cpm, 50 pM) and varying concentrations of unlabeled GnRH analogs. We have found previously that equilibrium binding is achieved after 21 h and stable for up to 30 h (Flanagan et al., 1998) . The incubation was terminated by the addition of cold polyethylenimine (0.01%; PEI) and immediate filtration through glass-fiber filters (GF/C; Whatman, Maidstone, UK) which were presoaked in 1% PEI. The filters were washed twice with 0.01% PEI and the retained radioactivity was counted. Nonspecific binding was determined in the presence of 1 M antagonist 27.
Data Reduction. IP assays were performed at least three times in duplicate and competition binding assays in triplicate. Four-parameter nonlinear curve fitting (Prism; GraphPad Software Inc., San Diego, CA) was used to estimate the peptide concentrations required to stimulate half-maximal IP production (EC 50 ) and to half-maximally inhibit the binding of the radioligand (IC 50 ). K i values were calculated using the Cheng-Prusoff equation (Cheng and Prusoff, 1973) . K d and B max values were determined using nonlinear curvefitting (Prism) of homologous competition binding assays (Munson and Rodbard, 1980; Klotz, 1982; Motulsky, 1999 -NHEt]-GnRH, was not affected by the Glu 7.32(301) Gln mutation in the mouse GnRH receptor (Flanagan et al., 1994) . To test whether this is a general phenomenon in mammalian GnRH receptors, binding affinities of a series of GnRH analogs with different D-amino acid substitutions in position six were characterized in the wild-type human receptor and in the Asp 7.32(302) Asn mutant (Fig. 3) . As expected for the wild-type receptor (Karten and Rivier, 1986; Sealfon et al., 1997) -NHEt]-GnRH, showed higher affinity (7.0-to 45-fold) than native GnRH (Tables 1 and 2, Fig. 3 (Table 2) (Table  1 ). In the mutant receptor, the affinities of the three analogs with D-amino acids in position six and Arg in position eight were 137-to 784-fold higher than the affinity for (native) GnRH ( (Fig. 3 , Table 2 ).
Incorporation of a 6,7 ␥-Lactam Enhances Binding to the Receptor. Because D-amino acid substitutions in position six are thought to stabilize a high-affinity conformation of GnRH (Monahan et al., 1973) , the high affinity of the mutant receptor for peptides with D-amino acids in position six suggests that conformationally constrained peptides may be less sensitive to the Asp 7.32(302) mutation. However, part of the enhanced affinity may be contributed by an interaction of the amino acid side chain (e.g., D-Trp) with a receptor residue. To test whether the high affinity is caused predominantly by the conformational constraint of the D-amino acid, peptides with a conformational constraint, in which there is no side chain, were examined. Introduction of a ␥-lactam moiety in place of residues six and seven is reported to impose a peptide conformation, which is similar to that stabilized by D-amino acid modifications (Freidinger et al., 1980) . Consistent with the previous report (Freidinger et al., 1980) , [6,7 ␥-lactam]-GnRH exhibited higher affinity than GnRH for the wild-type GnRH receptor (5.0-fold; Table 2 ). This result is similar to the increase found with D-amino acid substitutions in position six of GnRH (Table 2) . [6,7 ␥-Lactam]-GnRH also had high affinity for the Asp 7.32(302) Asn mutant GnRH receptor (K i ϭ 4.66 Ϯ 0.36 nM; Table 1), which was 45.5-fold higher than the affinity for native GnRH (Table  2 ). This shows that the ␥-lactam constraint enhances the affinity of GnRH for both the wild-type and mutant receptors (Fig. 4, Table 1 ). [6,7 ␥-Lactam]-GnRH had similar affinity for both the wild-type receptor (K i ϭ 1.37 Ϯ 0.07 nM) and the mutant receptor (K i ϭ 4.66 Ϯ 0.36 nM, Table 1 ). Similar to the D-amino acid substitution in position six, incorporation of 6,7 ␥-lactam enhanced binding affinity more in the mutant receptor than in the wild-type receptor. These results show that when the conformation of GnRH is constrained (6,7 ␥-lactam or D-amino acid in position six), Asp 7.32(302) of the Another class of conformationally constrained GnRH analogs includes the GnRH antagonists. The novel antagonist, antagonist 129-62, which has a 6,7 ␥-lactam, and antagonist 26, which has D-Lys 6 , had similar high affinities for the wild-type and mutant receptors (Table 1, Fig. 5) .
GnRH II, which occurs naturally in the human brain (White et al., 1998) ]-GnRH (Millar et al., 1989) . This suggests that the combination of substitutions in positions five, seven, and eight allows the peptide to bind with relatively high affinity, independently of interactions that involve Arg 8 , possibly by stabilizing a high affinity conformation (de L Milton et al., 1983) . GnRH II had similar affinity for the wild-type (K i ϭ 193.7 Ϯ 28.5 nM) and mutant receptors (K i ϭ 213.3 Ϯ 72.4 nM; Table 1 (Fig. 6 ). GnRH displayed a 44-fold decrease in potency at the mutant receptor (EC 50 ϭ 12.6 Ϯ 1.78 nM) relative to the wild-type receptor (EC 50 ϭ 0.29 Ϯ 0.07 nM; Fig. 6 ). This decrease in potency is consistent with the decreased affinity of the mutant receptor for native GnRH. However, the mutant receptor also exhibited a decreased E max value for GnRH (Fig. 6, Table 3 ), suggesting that the mutation may induce partial uncoupling of the receptor from intracellular signaling. Surprisingly, ligands that showed no decrease in affinity for the mutant receptor also exhibited decreased IP production in the mutant receptor (Table 3 , Fig. 6 ). This shows that the effect of the mutation on cytosolic signaling is distinct from its effect on binding affinity for GnRH.
Discussion
The basic Arg residue in position eight of GnRH is required for high-affinity binding to mammalian GnRH receptors (Millar et al., 1989) . The proposal that Arg 8 may be involved in an electrostatic interaction with an acidic residue in the GnRH receptor (Hazum, 1987) was examined in the mouse GnRH receptor, where it was found that the Glu 7.32(301) residue confers specificity for GnRH with Arg in position eight (Flanagan et al., 1994) . Despite the demonstrated functional importance of Glu 7.32(301) , this residue is not conserved in the human GnRH receptor, which has Asp 7.32(302) instead (Chi et al., 1993) . The carboxyl side chain of both residues suggests that Asp 7.32(302) can potentially perform the same functions in the human GnRH receptor as Glu 7.32(301) does in the mouse receptor and computational models of both rodent and human receptors have (Shinitzky et al., 1976) , which consists of a ␤-II-bend involving the Tyr 5 -Gly 6 -Leu 7 -Arg 8 residues (Monahan et al., 1973) . Incorporation of a D-amino acid in position six (Momany, 1976) or a ␥-lactam in positions six and seven (Freidinger et al., 1980 ) is proposed to stabilize this conformation and results in an increased GnRH potency (Monahan et al., 1973; Freidinger et al., 1980 GnRH more than that of GnRH (Table 2) (Davidson et al., 1996a; Flanagan et al., 2000) . Comprehensive analysis shows that the interaction of these receptor residues with native GnRH is similar to their interaction with constrained analogs. Mutation of these residues decreases receptor recognition of native and constrained analogs of GnRH to the same extent, suggesting that both native GnRH and constrained analogs interact with these residues (Davidson et al., 1996; Flanagan et al., 2000) . Thus, the ability of the ligand conformational constraint to overcome a receptor mutation is specific for the 7.32(302) . This suggests that both residues have roles in stabilizing a high affinity conformation of unconstrained GnRH. Arg 8 has been proposed to have two distinct roles in high-affinity binding: an intramolecular interaction that stabilizes a high-affinity peptide conformation (Shinitzky et al., 1976) and an intermolecular electrostatic interaction with an acidic group in the receptor (Hazum, 1987; Flanagan et al., 1994 7.32(302) may be required to induce a high-affinity conformation in unconstrained, native GnRH, the absence of this interaction with constrained analogs suggests that the interaction that induces the high-affinity conformation is transient. It has been suggested that residues on the extracellular surface of the TRH receptor form a initial ligand recognition site (Perlman et al., 1997) and that TRH binds sequentially with the surface binding site, and then with the transmembrane binding pocket (Colson et al., 1998 (Davidson et al., 1996; Flanagan et al., 2000) , after assuming a high affinity conformation. Thus, contrary to the initial hypothesis of an electrostatic interaction in the ligandreceptor complex, we show that the basis of receptor selectivity for mammalian GnRH seems to be the ability of Asp 7.32(302) to induce a high affinity conformation in native GnRH.
Cytosolic signaling assays showed that GnRH had decreased potency at the Asp 7.32(302) Asn mutant receptor, consistent with its decreased affinity. However, the E max value for GnRH was lower in the mutant receptor, suggesting that the mutation destabilizes the activated receptor conformation (Samama et al., 1993) . Several agonists, which showed no decrease in affinity for the mutant receptor, nevertheless showed decreased stimulation of IP production. This suggests that the Asp 7.32(302) side chain has a role stabilizing the activated receptor conformation. The apparent decreased efficacy of ligands that had unchanged affinity suggests that this function is distinct from its role in ligand selectivity. A previous study reported that mutagenesis of extracellular loop three of the ␤ 2 -adrenergic receptor also affected receptor activation (Zhao et al., 1998) .
In conclusion, the wild-type human GnRH receptor recognizes and binds ligands in a specific conformation that can be stabilized by ligand modifications. We show that the Asp 7.32(302) side chain determines selectivity for Arg 8 -containing GnRH. However, certain ligand conformational constraints overcome the decrease in affinity that results from substitution of Arg 8 and Asp 7.32(302) . This suggests that Asp 7.32(302) determines selectivity for Arg 8 -containing GnRH by its ability to induce a high-affinity conformation in the ligand. We propose that unconstrained, Arg 8 -containing, native GnRH interacts transiently with Asp 7.32(302) , which induces a high affinity conformation in the ligand, before it interacts with a final ligand binding pocket, which excludes Asp 7.32(302) . This further definition of the mechanism of ligand recognition improves our conceptual models of GnRH receptor-ligand interaction.
